| Identification | Back Directory | [Name]
PI3K inhibitor | [CAS]
1202884-94-3 | [Synonyms]
CAY10626
PI3K inhibitor
Antitumor Drug
N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-yl-7-(2,2,2-trifluoroethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]phenyl}carbamoyl)amino]benzamide
BenzaMide, N-[2-(diMethylaMino)ethyl]-N-Methyl-4-[[[[4-[4-(4-Morpholinyl)-7-(2,2,2-trifluoroethyl)-7H-pyrrolo[2,3-d]pyriMidin-2-yl]phenyl]aMino]carbonyl]aMino]- | [Molecular Formula]
C31H35F3N8O3 | [MDL Number]
MFCD18251469 | [MOL File]
1202884-94-3.mol | [Molecular Weight]
624.66 |
| Chemical Properties | Back Directory | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 15 mg/ml; DMSO: 15 mg/ml; DMSO:PBS (pH 7.2) (1:10): 0.1 mg/ml | [form ]
A crystalline solid | [pka]
13.74±0.70(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Description]
The PI3Kinases are important downstream effectors of KRAS signaling. In preclinical studies, buparlisib (BKM120), a PI3K inhibitor, when combined with MEK
inhibitor (PD1056309) led to significant synergistic activity in KRAS mutant
NSCLC cell lines. | [Uses]
PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has IC50s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer[1]. | [Definition]
ChEBI: CAY10626 is a member of ureas. | [in vivo]
PI3K-IN-22 (25 mg/kg; i.v.) suppresses phosphorylation of Akt T308, Akt S473 and S6K in MDA361 breast tumor cells up to 8 h in MDA361 tumor bearing nude mice demonstrated by biomarker studies[1].
PI3K-IN-22 (50, 25, 10 mg/kg; i.v.; once daily for 5 days weekly; 2 rounds) shows good antitumor efficacy in MDA361 tumor xenograft nude mice model[1].
PI3K-IN-22 (25 mg/kg; i.v.; a single dose) has a blood concentrationsat value of 1731 ng/mL at 8 h[1]. | Animal Model: | MDA361 tumor xenograft nude mice model[1] | | Dosage: | 50, 25, 10 mg/kg | | Administration: | i.v., once daily for 5 days weekly (2 rounds) | | Result: | Exhibited significant tumor regression in 50 mg/kg and no tumor regrowth until day 32.
Exhibited tumor growth inhibition in 25 and 10 mg/kg. |
| [IC 50]
PI3Kα: 0.9 nM (IC50); mTOR: 0.6 nM (IC50) | [References]
[1] Chen Z, et al. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors. J Med Chem. 2010 Apr 22;53(8):3169-82. DOI:10.1021/jm901783v |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Abcam Limited
|
| Tel: |
+1 (877) 774-8286 |
| Website: |
http://www.abcam.com |
|